Alzheimer's disease

'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed
Endpoints
Wed, 02/9/22 - 10:11 am
Alzheon
Alzheimer's disease
ALZ-801
clinical trials
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Reuters
Mon, 02/7/22 - 11:26 pm
Biogen
Aduhelm
FTC
SEC
Alzheimer's disease
Lilly slows FDA submission of Alzheimer's drug after Medicare decision
BioPharma Dive
Thu, 02/3/22 - 11:43 pm
Eli Lilly
donanemab
Alzheimer's disease
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year
Fierce Pharma
Thu, 02/3/22 - 11:45 am
Biogen
earnings
Aduhelm
Alzheimer's disease
A year of TIGIT (and Alzheimer’s) for Roche
EP Vantage
Thu, 02/3/22 - 10:53 am
Roche
Tigit
tiragolumab
Alzheimer's disease
CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say
Fierce Pharma
Tue, 02/1/22 - 10:50 am
CMS
Biogen
Aduhelm
Eli Lilly
Roche
Alzheimer's disease
Lithium-Sparing Alzheimer’s Therapy has Strong Benefit-to-Risk Profile
BioSpace
Fri, 01/28/22 - 10:30 am
Alzamend Neuro
AL001
clinical trials
lithium
Alzheimer's disease
Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug
BioPharma Dive
Thu, 01/27/22 - 11:44 pm
Cortexyme
FDA
Alzheimer's disease
Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on
Endpoints
Thu, 01/27/22 - 10:58 am
Biogen
Alzheimer's disease
clinical trials
clinical trial diversity
Aduhelm
A senior Biogen commercial exec exits Alzheimer's unit amid exodus as Aduhelm woes mount
Endpoints
Thu, 01/27/22 - 10:42 am
Biogen
Alzheimer's disease
Aduhelm
3 Clinical Trials to Watch in the First Half of 2022
Motley Fool
Sat, 01/22/22 - 02:20 pm
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Roche
Alzheimer's disease
gantenerumab
AbbVie
cystic fibrosis
Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm
Fierce Biotech
Fri, 01/21/22 - 11:13 am
Eli Lilly
Biogen
Alzheimer's disease
Aduhelm
donanemab
clinical trials
David Ricks
With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment
Stat
Fri, 01/14/22 - 10:56 am
Medicare
Aduhelm
Biogen
CMS
racial disparity
Alzheimer's disease
Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years
Endpoints
Thu, 01/13/22 - 10:26 pm
Biogen
Aduhelm
CMS
drug reps
Medicare
Alzheimer's disease
FDA denies Denali's Takeda-partnered Alzheimer's drug from entering clinic
Fierce Biotech
Thu, 01/13/22 - 10:19 pm
Denali Therapeutics
Takeda
Alzheimer's disease
FDA
DNL919
For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst
Fierce Pharma
Wed, 01/12/22 - 11:01 am
CMS
Biogen
Aduhelm
Medicare
clinical trials
Alzheimer's disease
Where Will Cassava Sciences Be in 1 Year?
Motley Fool
Fri, 01/7/22 - 10:45 am
Cassava Sciences
Simulfilam
clinical trials
Alzheimer's disease
Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?
Fierce Pharma
Thu, 01/6/22 - 12:59 pm
Biogen
Aduhelm
Medicare
CMS
Alzheimer's disease
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Mon, 01/3/22 - 10:45 pm
Biogen
Eisai
lecanemab
Alzheimer's disease
fast track
FDA
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Tue, 12/28/21 - 10:55 am
Biogen
Eisai
lecanemab
FDA
Aduhelm
fast track
Alzheimer's disease

Pages